...who succeeds Rob Quinn, was CFO and COO at Vyome Therapeutics Inc.Metabolic and endocrine disorders company Viking...
...time he will join the board and become president-emeritus. BC Staff Moderna Inc. MorphoSys AG Allen Institute Silence Therapeutics plc Verastem Inc. Viking...

...Perceptive Advisors, EcoR1 Capital, Citadel's Surveyor Capital and Logos Capital. Joining them were existing investors Viking...

...by Venrock Healthcare Capital Partners (VHCP) and brought in new investors OrbiMed Advisers, Redmile Group, Viking...

...closes $80M series CPharvaris GmbH raised $80 million in a series C round led by Viking...

...therapies and biomarkers.Co-founder and CEO Kareem Barghouti said the seed round, which was co-led by Viking...

...Capital Management, Foresite Capital, Janus Henderson Investors, Logos Capital, OrbiMed Advisors, T. Rowe Price, Venrock, Viking...

...Price Associates, Tybourne Capital Management, Vida Ventures, Viking...

...with centralized services for collection, receipt, storage, protection, processing, tracking, retrieval, packaging and distribution.  Surveyor, Viking...
...Inc. raised $115 million in a series B round co-led by Citadel’s Surveyor Capital and Viking...

...Co. The existing investors joining OrbiMed is continuing to back the company are Nextech Invest, Viking...

...a DGAT1 inhibitor, in Phase I testing for metabolic disorders. Ligand Pharmaceuticals Inc. (NASDAQ:LGND) and Viking...